“Long-Term Safety and Disease Control of Ruxolitinib Cream Among Adolescents With Atopic Dermatitis: Results From Two Phase 3 Studies”. 2022. SKIN The Journal of Cutaneous Medicine 6 (2): s28. https://doi.org/10.25251/skin.6.supp.28.